Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Astermark

Showing results (11-20 of 92) with videos related to

Pageof 10
Sort By:
European Journal of Haematology|January 7, 2015
Non-genetic risk factors and their influence on the management of patients in the clinicTeresa Álvarez, Immaculada Soto, Jan Astermark
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 22, 2021
A comparison of MyPKFiT and WAPPS-Hemo as dosing tools for optimizing prophylaxis in patients with severe haemophilia A treated with Octocog alfaAlexandros Arvanitakis, Erik Berntorp, Jan Astermark
Seminars in Thrombosis and Hemostasis|June 29, 2006
Inhibitor development in hemophiliacs: the roles of genetic versus environmental factorsChristine A Lee, David Lillicrap, Jan Astermark
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|December 2, 2010
Physical activity and joint function in adults with severe haemophilia on long-term prophylaxisMohamed Khawaji, Jan Astermark, Kristina Akesson, et al.
British Journal of Haematology|September 17, 2013
Long-term anti-FVIII antibody response in Bethesda-negative haemophilia A patients receiving continuous replacement therapyJenny Klintman, Andreas Hillarp, Erik Berntorp, et al.
Lakartidningen|April 26, 2023
[Factor XIII deficiency - not only a congenital bleeding disorder]Ulf Schött, Jan Astermark, Anna Zdanowski, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 30, 2023
Impact of timing of prophylaxis commencement, F8 genotype and age on factor consumption and health-related quality of life in patients with severe haemophilia AAlexandros Arvanitakis, Pål Andre Holme, Erik Berntorp, et al.
Thrombosis and Haemostasis|June 4, 2008
Cost and outcome: comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitorKatarina Steen Carlsson, Jan Astermark, Sharyne Donfield, et al.
Blood Reviews|May 20, 2008
From theory to practice: applying current clinical knowledge and treatment strategies to the care of hemophilia a patients with inhibitorsEdward D Gomperts, Jan Astermark, Alessandro Gringeri, et al.
Journal of Thrombosis and Haemostasis : JTH|January 7, 2026
Non-carrier mothers of hemophilia A patients with Inv22 inversions often have other rearrangementsEric Manderstedt, Christina Lind-Halldén, Christer Halldén, et al.
Pageof 10

Showing results (11-20 of 92) with videos related to

Sort By:
Pageof 10
European Journal of Haematology|January 7, 2015
Non-genetic risk factors and their influence on the management of patients in the clinicTeresa Álvarez, Immaculada Soto, Jan Astermark
Haemophilia : the Official Journal of the World Federation of Hemophilia|March 22, 2021
A comparison of MyPKFiT and WAPPS-Hemo as dosing tools for optimizing prophylaxis in patients with severe haemophilia A treated with Octocog alfaAlexandros Arvanitakis, Erik Berntorp, Jan Astermark
Seminars in Thrombosis and Hemostasis|June 29, 2006
Inhibitor development in hemophiliacs: the roles of genetic versus environmental factorsChristine A Lee, David Lillicrap, Jan Astermark
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|December 2, 2010
Physical activity and joint function in adults with severe haemophilia on long-term prophylaxisMohamed Khawaji, Jan Astermark, Kristina Akesson, et al.
British Journal of Haematology|September 17, 2013
Long-term anti-FVIII antibody response in Bethesda-negative haemophilia A patients receiving continuous replacement therapyJenny Klintman, Andreas Hillarp, Erik Berntorp, et al.
Lakartidningen|April 26, 2023
[Factor XIII deficiency - not only a congenital bleeding disorder]Ulf Schött, Jan Astermark, Anna Zdanowski, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 30, 2023
Impact of timing of prophylaxis commencement, F8 genotype and age on factor consumption and health-related quality of life in patients with severe haemophilia AAlexandros Arvanitakis, Pål Andre Holme, Erik Berntorp, et al.
Thrombosis and Haemostasis|June 4, 2008
Cost and outcome: comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitorKatarina Steen Carlsson, Jan Astermark, Sharyne Donfield, et al.
Blood Reviews|May 20, 2008
From theory to practice: applying current clinical knowledge and treatment strategies to the care of hemophilia a patients with inhibitorsEdward D Gomperts, Jan Astermark, Alessandro Gringeri, et al.
Journal of Thrombosis and Haemostasis : JTH|January 7, 2026
Non-carrier mothers of hemophilia A patients with Inv22 inversions often have other rearrangementsEric Manderstedt, Christina Lind-Halldén, Christer Halldén, et al.
Pageof 10